Canaccord Genuity reaffirmed their buy rating on shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) in a research note published on Tuesday morning. Canaccord Genuity currently has a $22.00 target price on the stock.

A number of other equities research analysts also recently weighed in on AQXP. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, August 15th. BidaskClub upgraded shares of Aquinox Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, August 4th. Cantor Fitzgerald reiterated a buy rating and issued a $28.00 price target on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Needham & Company LLC reiterated a buy rating and issued a $25.00 price target on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Finally, ValuEngine downgraded shares of Aquinox Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company has an average rating of Hold and a consensus target price of $22.50.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at $10.56 on Tuesday. Aquinox Pharmaceuticals has a 1 year low of $10.20 and a 1 year high of $19.97.

COPYRIGHT VIOLATION WARNING: “Aquinox Pharmaceuticals’ (AQXP) “Buy” Rating Reaffirmed at Canaccord Genuity” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/11/22/aquinox-pharmaceuticals-aqxp-buy-rating-reaffirmed-at-canaccord-genuity.html.

A number of large investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. increased its stake in Aquinox Pharmaceuticals by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock valued at $4,010,000 after acquiring an additional 5,046 shares during the last quarter. Vanguard Group Inc. increased its stake in Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after acquiring an additional 17,455 shares during the last quarter. University of Notre Dame DU Lac grew its stake in shares of Aquinox Pharmaceuticals by 11.1% during the third quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock worth $2,700,000 after buying an additional 19,066 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Aquinox Pharmaceuticals by 10.0% during the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock worth $2,028,000 after buying an additional 11,035 shares during the last quarter. Finally, Nexthera Capital LP bought a new stake in shares of Aquinox Pharmaceuticals during the second quarter worth $1,276,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.